Abstract
Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
